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Abstract: Exosomes are a subgroup of extracellular vesicles containing a huge number of bioactive
molecules. They represent an important means of cell communication, mostly between different
cell populations, with the purpose of maintaining tissue homeostasis and coordinating the adaptive
response to stress. This type of intercellular communication is important in the cardiovascular field,
mainly due to the fact that the heart is a complex multicellular system. Given the growing interest
in the role of exosomes in cardiovascular diseases and the numerous studies published in the last
few decades, we focused on the most relevant results about exosomes in the cardiovascular filed
starting from their characterization, passing through the study of their function, and ending with
perspectives for their use in cardiovascular therapies.
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1. Introduction
Exosomes (EXOs) are a subgroup of extracellular vesicles (EVs), ranging in size from 30 to
100 nm, released by different cell types [1]. To date, they were found in numerous body fluids such
as plasma, serum, saliva, amniotic fluid, breast milk, and urine; moreover, they are also released
in cell culture media [2]. EXOs are rich in bioactive molecules, including DNA, messenger RNAs
(mRNAs), microRNAs (miRNAs), and proteins; moreover, by transferring their bioactive cargos, they
are important drivers in intercellular communication.
Many studies focused on the complex mechanisms of EXO biogenesis, secretion, and cargo
loading; in fact, several steps are needed from the formation of intraluminal vesicles until fusion with
the plasma membrane, passing through the loading of cargos. EXOs generate from the invagination
of endosomes which form multivesicular bodies (MVBs) and they are secreted through the fusion
of MVBs with the cell membrane; this process is mediated by the Rab family of proteins [3]. EXO
composition is dependent on the cell type of origin, and is largely reflective of its physiological or
pathological state. This means that the secretion, content, and function of EXOs strongly vary in
response to changes in the cell microenvironment [4]. The precise selection of EXO cargo is not
yet well clarified, although it seems that the protein sorting into EXOs is principally managed by
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endosomal sorting complexes required for transport (ESCRT) or by sphingolipids (ESCRT-dependent
or ESCRT-independent pathways) [5,6]. Observations about RNA species suggested that some RNAs
present motifs that may represent elements that favor their loading into EXOs [7] (Figure 1). Protected
from the EXO lipid bilayer, protein and RNA cargo can persist in the extracellular space without
undergoing degradation. Once secreted, EXOs can enter neighboring target cells or travel into the
body fluids to even reach cells in distant districts; it was demonstrated that target cells internalize
EXOs through a variety of methods such as endocytosis, membrane fusion, or ligand receptor binding,
depending on source cells, target cells, and environments [8,9].
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Figure 1. Release of exosomes (EXOs) and a sorting model. (A,B) Release of EXOs upon exocytic 
fusion of multivesicular bodies (MVBs) with the plasma membrane; arrows indicate the fusion profile. 
PM: plasma membrane; MVB: multivesicular body. Scale bars: 200 nm. (C) A proposed model for 
sorting of cargo into different MVB subpopulations. Different hypothetical MVB subclasses with 
distinct populations of intraluminal vesicles (red, green, and blue) are shown. Whether the MVBs 
contain a mixture of different intraluminal vesicles as depicted in the figure is not known. Sorting of 
cargo may already start within the biosynthetic pathway, at the plasma membrane, or within an 
endosomal compartment. Modified from Reference [1]. 
This evidence leads EXOs to become an attractive focus in biomedical research for investigating 
their role in different physiological and pathological settings as signaling mediators, biomarkers, and 
potential therapeutic targets.  
Recently, EXOs earned interest in the cardiovascular field due to the fact that, in a multicellular 
system, such as the heart, communication between different and not always close cells plays a 
fundamental role in the maintenance of physiological cardiac homeostasis and in the adaptive 
response to stress; EXOs are suitable candidates to have a central role in intercellular exchanges of 
information. It was demonstrated that they are involved in a wide range of cardiovascular processes, 
both physiological and pathological, with beneficial or detrimental activity [10–13]. 
EXOs are released practically from all cells in the cardiovascular system and it was shown that 
stress conditions such as hypoxia or inflammation modulated their cargos and their release in 
conjunction with the target cells, contributing to improving or to impairing heart function [14] (Figure 
2). Furthermore, Waldenström and colleagues highlighted the heterogeneity of microvescicles (MVs) 
and EXOs from the same cell type; in cardiomyocytes (CMs), 80% of the vesicles from the main cell 
population resulted positive for flotillin-1 surface antigen, while 30% were positive for carveolin-3, a 
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(MVs) and EXOs from the same cell type; in cardiomyocytes (CMs), 80% of the vesicles from the main
cell population resulted positive for flotillin-1 surface antigen, while 30% were positive for carveolin-3,
a protein exclusively present in cardiac muscle cells [15]. A part of them displayed an electron-dense
appearance and another part displayed an electron-lucent interior. They hypothesized that these
differences could imply a difference also in their cargo and target cells [15] (Figure 2).
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The multitude of cardiovascular processes in which EXOs are involved affords them great potential
in the diagnostic and therapeutic fields as a novel alternative to whole-cell therapies. This is because
they are more stable than cells, as well as being biocompatible and non-immunogenic; moreover,
they are resistant to cryo-conservation without degrading [17]. However, it is necessary to say that
EXO collection, isolation, and purification processes are still undergoing standardization. In fact,
as highlighted by Tang and colleagues, different isolation methods lead to a discrepancy in purity, size,
and concentration of EXOs and their cargo [18]. It follows that the populations of vesicles isolated with
different methods are not homogeneous, and probably contain more than just exosomes. The lack of
standardized methods can explain the difficulties in reproducibility and the discrepancies of results of
some studies.
In this review, we summarize the findings about the role of EXOs in the cross-talk between the
different cardiac cell populations and their potential as diagnostic biomarkers and therapeutic means
in cardiovascular diseases.
2. Exosomes from Different Cardiac Cells, Their Content, and Their Ability to Modulate
Cell Behavior
A large part of heart volume is built by cardiac muscle, while the most abundant non-myocyte
cell type is represented by cardiac fibroblasts (CFs) that account for about 90% of non-muscle cells.
In contact with these cells, there are endothelial cells (ECs) that have important roles in cardiac
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homeostasis. Moreover, several studies highlighted the presence of resident cardiac-derived progenitor
cells (CPCs) that are involved in the post-injury response [19,20]. The presence of such cells in the heart
suggests the importance of heterocellular communication and the necessity to investigate the way
in which this communication takes place. In this sense, EXOs are the main candidate for mediation
between the various cell populations.
2.1. Cardiomyocytes
The first evidence that CMs release EXOs was provided by Gupta et al., who showed that
EXOs were released both in physiological conditions and after hypoxia, with an increase in
their release and in their content of heat-shock protein 60 (HSP60) under stress conditions [14].
A further study demonstrated that HSP60s contained in EXOs were bound to the membrane
and were not released, preventing the pro-apoptotic effects induced by circulating HSP60 [10].
In the same study, proteomic analysis revealed that EXOs from primary CMs contained a pool
of proteins that were common, but differed in amount, in EXOs obtained from CMs which
underwent ethanol or hypoxia/reoxygenation stimuli. This pool included HSP60, tropomyosin-α,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), myomesin, myosin-binding protein C,
α-Cristallin B chain, and valosin-containing protein (VCP), while HSP27 and HSP90 were found
only in hypoxia/reoxygenation-derived EXOs [10]. Moreover, EXOs from CMs that underwent
hypoxia treatment seemed to promote apoptosis in nearby CMs due to the presence of tumor necrosis
factor-α (TNF-α) in their cargo, favored by the activation of hypoxia-inducible factor-1α (HIF-1α) [12].
Another study demonstrated that hypoxic condition enriched EXOs in miRNA-30a that was efficiently
transferred between CMs, favoring the maintenance of autophagic response probably through targeting
beclin-1 and the Atg12 gene. Furthermore, CM transfection with a miRNA-30a inhibitor or a block of
EXO release from CMs attenuated hypoxia-induced apoptosis [21]. Other miRNAs present in CM
EXOs after hypoxia were found to be involved in the modulation of the apoptotic pathway; Zhang
and colleagues indicated that rno-miR-21-5p, rno-miR-378-3p, rno-miR-152-3p, and let-7i-5p were
upregulated after 48 h of hypoxia and, in particular, rno-miR-21-5p and rno-miR-378-3p appeared to
have anti-apoptotic effects [11].
Since cardiovascular impairment is a major complication of diabetes, several studies focused
on the involvement of EXOs in heart failure in diabetic conditions. For diabetic patients, physical
exercise is important to decrease the possibility of developing cardiac dysfunction. Chaturvedi
and colleagues studied EXOs released from cardiac muscle during exercise. They discovered that
so-stimulated CM EXOs contained an elevated amount of mmu-mir-29b and mmu-mir-455, and that
these miRNAs prevented the activation of matrix metalloproteinase 9 (MMP9), preserving the heart from
the development of fibrosis and myocyte uncoupling [16]. This evidence served as a starting point to
explore CM EXOs as a therapy for cardiac remodeling, since MMP9 inhibitors were not successful [16].
It was proven that EXOs from CMs could be internalized from other cells such as CFs and ECs,
promoting the modulation of receiving cell behaviors. For example, the presence of CM EXO DNA in
the CF cytosol and nucleus was shown, and this promoted gene expression modification. In particular,
175 genes were upregulated and 158 were downregulated in fibroblasts treated with CM EXOs [15].
A recent study indicated that the interaction between CMs and CFs is important in the progression
of chronic heart failure, promoting the development of cardiac hypertrophy and dysfunction [22].
High expression of hsa-miR-217 in pathological rat CMs seemed to favor its release through EXOs that
are taken up by CFs, promoting their proliferation and activation, and leading to heart fibrosis [22].
The close anatomical and functional relationship between CMs and ECs implicates the ability of
CMs to communicate also with ECs and vice versa, above all during stress and pathological conditions.
Wang et al. investigated the role of EXOs in CM and EC cross-talk in diabetic rats, showing that EXOs
from pathological CMs were rich in rno-miR-320 and poor in rno-miR-126. This cargo modulated
insulin-like growth factor-1 (IGF-1), HSP20, and Ets2 expression in ECs, promoting the downregulation
of these genes; this seemed to lead to an inhibition of EC proliferation, migration, and tube-like
Cells 2019, 8, 166 5 of 17
formation [23]. On the contrary, deprivation of glucose, another stress condition, enhanced the
release of EXOs from CMs with a glucose-dependent regulation of the cargo; CMs in normal culture
conditions were shown to release EXOs that contained proteins mainly related to cell structure, growth,
and survival, as well as mmu-miR-17, 20a, 23b, 30b, and 132. Contrariwise, CMs deprived of glucose
produced EXOs rich in proteins involved in cell metabolism and in the proenergetic pathway, as well
as mmu-miR-16, 17, 19a, 19b, 21, 23a, 23b, 30c, 125b-5p, 126-3p, 301a, and 301b [24] (Figure 3).
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2.2. Cardiac Fibroblasts
CFs are the main cells involved in extracellular matrix (ECM) turnover, and, due to their secretory
activity, they influence the physiology of other cells in the heart [25]. Despite this, only few works
investigated CF EXO composition and activities. One was performed by Cosme and colleagues, who
mapped and compared the proteomic profile of whole-CF lysate, CF secretome, and CF EXO content
in normoxic and hypoxic conditions (Figure 4).
Focusing on EXOs, they found that normoxic and hypoxic conditions modified the number and
the content of CF EXO proteins; under normoxic conditions, they identified 1752 proteins, while,
following hypoxia, there were 1616 proteins. Moreover, comparing normoxia vs. hypoxia, 144 proteins
resulted differentially expressed. Hypoxic conditions promoted EXO enrichment in ECM proteins such
as multiple collagen type, perlecan, and fibronectin. Furthermore, they found an overrepresentation
of mitochondria-associated proteins, and hypothesized that EXOs could be used by cells to remove
dysfunctional mitochondria during stress conditions [25].
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They also demonstrated that, depending on the time of co-treatment, CF EXOs had different
effects on CM viability; if CF EXOs were added to CMs immediately before CM hypoxia treatment,
they improved CMs viability; contrariwise, they reduced CM viability if added before the CM
reoxygenation phase.
In addition to proteins, CF EXOs also contain miRNAs. It was shown that the 25.5% of fibroblast
EXO miRNAs were represented by star miRNAs and, interestingly, Bang et al. discovered that fibroblasts
were rich in rno-miR-21, while fibroblast-derived EXOs were enriched with rno-miR-21*. From their
study, it seemed that rno-miR-21* was transported from CFs to CMs via EXOs, and that it could be
involved in C hypertrophy [26]. Tian and colleagues demonstrated that treatment with TNF-α favored
the enrichment of CF EXOs with rno-miRNA-27a, rno-miRNA-28a, and rno-miRNA-34a. These miRNAs
were transferred to CMs promoting the expression of hypertrophic markers such as atrial natriuretic
peptide and β-myosin heavy chain in CMs [13].
The use of EXOs by CFs to communicate with CMs was also investigated by Lyu and colleagues,
who noted that angiotensin II (AngII)-treated CFs stimulated the release of EXOs that ere taken up by
CMs. These EXOs in turn upregulated AngII expression together with the expression of its receptors
in CMs, enhancing AngII-related cardiac hypertrophy [27].
From these studies, we can deduce that CFs utilize EXOs to communicate predominantly
with CMs.
2.3. Endothelial Cells
Heart microvasculature is fu damental for card ac health and cardiac tissue homeostasis. ECs,
which form the endothelial barrier betwe n blood and surrounding tissues, have a primary role
in the maintenance of this homeostasis, especially following stress signals such as inflammation or
hypoxia. The response of ECs to str ss or damage signals leads not only to a release of growth factors
and cytokines, but also EXOs that mediate their communication with each other and with the other
cardiac compartments.
A study carried out in 2012 showed that ECs cultured under different conditions released EXOs
whose contents reflected cellular stress, varying in relation to the received stimuli [28]. Quantitative
proteomics and mRNA arrays revealed that EXOs from ECs that underwent hypoxia or inflammation
clearly differed from control EC EXOs; if stimulated with hypoxia, they presented a higher content of
proteins involved in ECM remodeling, such as fibronectin and collagen, and an enrichment in mRNAs
linked to stress response and apoptosis genes; if treated with TNF-α to mimic inflammation, EXOs
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resulted enriched in several factors concerning superoxide protection, immune response, and nuclear
factor κB (NF-κB) pathway [28].
EXOs are used by ECs to communicate with each other and, particularly, to manage angiogenesis.
It was found that delta-like 4 factor (Dll-4), an important factor that regulates angiogenesis, was present
into EXOs released from ECs overexpressing Dll-4, and that these EXOs were taken up by the
neighboring ECs. The transfer of these EXOs through ECs promoted the increase in angiogenesis
by inhibiting Notch signaling, without requiring cell–cell contact [29]. Another factor delivered
by EC EXOs, which resulted implicated in the modulation of angiogenesis and vessel formation,
is hsa-miR-214 [30]. Van Balkom and colleagues showed the transfer of this miRNA between ECs and
demonstrated that this caused the downregulation of ataxia telangiectasia mutated (ATM) in recipient
cells. ATM is responsible for the prevention of cell-cycle progression; thus, its downregulation means
a repression of cell senescence and an induction of the angiogenetic program [30].
In particular conditions such as peripartum cardiomyopathy, ECs, stimulated by 16-kDa
N-terminal prolactin fragment (16K PRL), overexpress miRNA-146a that exerts anti-angiogenic and
anti-proliferative effects on ECs. This miRNA is also secreted through EXOs release by ECs that
are efficiently taken up by CMs, thus modulating their activity [31]. Halkein et al. demonstrated
that EC EXOs, enriched in miR-146a, taken up by CMs, promoted the decrease of CM metabolic
activity and downregulated Erbb4, Notch1, and Interleukin-1 receptor associated kinase 1 (Irak1)
expression, proteins which are normally upregulated in the maternal heart, leading to the development
of peripartum cardiomyopathy [31].
2.4. Cardiac-Derived Progenitor Cells and Cardiosphere-Derived Cells
Several studies demonstrated that the adult heart contains a group of heterologous cells, senescent
in physiological conditions, capable of being activated by injuries and of differentiating into new
myocytes or vascular cells; these cells are named cardiac-derived progenitor cells (CPCs) [32,33]. These
cells spontaneously diffuse out from ex vivo cultures of heart tissue. When cultured in suspension,
CPCs have the tendency to form spherical aggregates, denominated cardiospheres (CDCs). These
aggregates differ from CPCs and present different properties [20].
It was shown that EVs can be released from CPCs and CDCs, and it was shown that EXOs were
the predominant fraction of EVs [34,35]. In 2014, Barile et al. studied the effects of conditioned medium
from CPCs, which contained EXOs, on the HL-1 cardiomyocytic cell line and on human umbilical vein
endothelial cells (HUVEC), finding that it decreased HL-1 cell apoptosis and promoted tube formation
in the HUVEC culture. MicroRNA transcriptional profiling of EV content underlined an enrichment
in hsa-miR-210, hsa-miR-132, hsa-miR-146a-3p, and hsa-miR-181, compared with the profiling of
fibroblasts EVs [36]. In particular, Barile and colleagues hypothesized that the presence of a high
amount of hsa-miR-210 sustained the anti-apoptotic effect, as it is associated with the downregulation
of its targets ephrin A3 and Protein-tyrosine-phosphatase 1 (PTP1), while the increased presence of
hsa-miR-132, associated with the functional downregulation of its target RasGap-p120, was indicated
as responsible for the angiogenetic effects [36]. The protection of CMs from apoptosis by CPC EXOs
could be sustained also by the content of mmu-miR-21, which seemed to downregulate programmed
cell death 4 (PDCD4) expression; indeed, this factor is involved in the miRNA-21/PDCD4 axis that
importantly mediates CM apoptosis induced by oxidative stress [37].
A recent study suggested that the cardioprotective capacity of CPCEXOs could be due also to the
presence of pregnancy-associated plasma protein-A (PAPP-A) on their surface [38]. The active form of
this protein cleaved Insulin-like growth factor binding protein-4 (IGFBP-4) promoting the release of
Insulin-like growth factor-1 (IGF-1), a key cardioprotective factor. Moreover, EXOs from CPCs favored
the phosphorylation of Insulin-like growth factor receptor (IGFR) and intracellular Extracellular-signal
regulated kinase 1 and 2 (Erk1/2) in CMs treated with staurosporine [38].
Regarding CDCs, Ibrahim and colleagues also showed that EXOs derived from them had
cardioprotective function. They resulted enriched in hsa-miR-146 compared to those of the
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fibroblasts [39]; this miRNA has known targets Irak1 and Traf6, two signaling mediators of the
Toll-like receptor (TLR)–NF-κB axis [40,41]. In this study, the exposure of CMs to an miR-146a mimic
promoted their protection against oxidative stress and, as a consequence, CM viability increased.
Furthermore, the knockout of miR-146a in mice (146a KO) significantly impaired heart function after
myocardial infarction (MI), also causing adverse tissue remodeling compared to wild-type (WT) mice
or miR-146a KO mice injected with an miR-146a mimic (146a KO-R) [39] (Figure 5). The authors
concluded that this evidence pointed to miRNA-146a potentially mediating the benefits of CDC EXOs.
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Most of the studies that investigated the role of CPC EXOs on different populations of infarcted
heart cells did not tak in consideration that, in physiological c ditions, CPCs are also exposed to
ypoxic conditions. In their work, Gray et al. paid attention to this and utilized EXOs from CPCs
ex sed t 3 h or 12 h of hypoxia in t eat d ECs and CFs. They po nted o t that 12-h hyp xic CPC
EXO significantly enhanced tube form ion in ECs and decr ased pro-fibrotic factor expression in
CFs, while 3-h hypoxic CPC EXOs or norm xic CP EXOs did not have such pronounced effects [42].
Interestingly they saw that hypoxic EXOs were poor in miRNA-320, miRNA-222, and miRNA-185
conten , correlated with anti-angiogenic, pro-apoptotic and anti-migrat on, and pro-fibrotic effects,
resp ctively [42].
A the beginning of 2018, Nie et al. published a paper in which they performed proteomic and
RNA sequencing analysis of the CPC secretome [43]. The results were in agreement with previous
studies and confirmed the pro-survival, pro-angiogenic, and pro-mitogenic effects of CPC EXOs
content. They found elevated levels of miRNA precursors and miRNAs that stimulate cell survival,
proliferation, and angiogenesis, such as hsa-miR-3615, hsa-miR-6087, hsa-miR-1244, and hsa-miR-3687,
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and, in addition to these, small and long non-coding RNAs. Interestingly, proteomic analysis revealed
that, within the EVs, 93% of proteins had their corresponding mRNA, suggesting that they were
captured during the translation process. Consequently, proteins also resulted to be implicated in cell
survival, proliferation, and angiogenesis [43].
3. Exosomes as Biomarkers in Cardiovascular Diseases
In addition to being internalized by neighboring cells, EXOs produced by cardiac cells are released
into the body fluids. This allows exploiting EXOs as biomarkers that indicate a pathological state,
considering that EXO content could vary in relation to it.
MicroRNAs are the most studied elements contained in EXOs for their role as new biomarkers in
cardiovascular diseases. The majority of miRNAs isolated from plasma contained EXOs and bound
to RNA-binding proteins, while only few miRNAs were free [44]; through analyzing the content of
circulating EXOs, it was and it will possible to identify miRNAs that, changing in quantity, can be
considered as biomarkers.
Focusing on cardiovascular diseases, different miRNAs were individualized for this purpose;
for example, hsa-miR-1 and hsa-miR-133a, two cardiac-specific miRNAs, were demonstrated to be
upregulated in serum from patients with acute coronary syndrome (ACS), and they were very likely
stored in EXOs [45].
In acute pathologies, such as ACS and acute myocardial infarction (AMI), it is very important
to rapidly individualize them. The classical biomarkers used to diagnose AMI are troponin and
creatinine kinase MB, which sometimes coordinate with other biomarkers. Troponin levels peak at 12 h
from the onset of cardiac damage, and their levels are proportional to the infarct size [46]. Recently,
circulating miRNAs were discovered that were upregulated in the plasma of AMI patients, which
reached their peak level earlier then troponin. An example was hsa-miR-208a; it was undetectable
in healthy patients, but clearly appeared in 100% of AMI patients after 4 h from the onset of chest
pain, very early compared to the appearance of detectable traces of troponin [47]. From the same
family, hsa-miR-208b was also evaluated as an AMI biomarker. It was found that this miRNA was
significantly increased in AMI patients within 12 h, making it a potentially good biomarker, but not
one superior to troponin as they have a similar trend. The same consideration was made for hsa-miR-1,
hsa-miR-133a, and hsa-miR-499 [48]. A research by Gidlöf et al. showed that the upregulation of
plasma levels of hsa-miR-208b and hsa-miR-499-5p corresponded to an increase in the risk of death
or heart failure, giving an indication of the prognosis [49]. Matsumoto and colleagues found that
three particular p53-responsive miRNAs enriched in circulating EXOs, hsa-miR-192, hsa-miR-194 and
hsa-miR-34a, were upregulated in the serum of AMI patients that experienced development of heart
failure within one year, leading them to be considered as possible prognostic markers [50].
Few studies analyzed the proteomic profile of EXOs found in the bloodstream of MI patients.
Cheow et al. identified six novel proteins that might be biomarkers of myocardial injury; these belonged
to complement activation (C1Q1A and C5), lipid metabolism (APOD and APOC3), and platelet
activation pathways (GP1BA and PPBP) [51].
Altogether, the studies reported above indicated that the heart releases characteristic EXOs
following the onset of injury. The content of these EXOs might be useful for an early diagnosis and
for hypothesizing, and thereby trying to prevent, a future prognosis. Some elements seem to be able
to help formulate a diagnosis earlier than those actually used, while others, added to the classical
analysis, could serve to pronounce a more precise diagnosis.
4. Exosomes as Therapeutic Agents in Cardiovascular Diseases
The possible use of EXOs as a substitute to whole-cell therapy received great interest. EXOs,
in fact, possess several advantages compared to cells for therapeutic use; they are biocompatible,
non-immunogenic, and non-tumorigenic; moreover, they are physiologically more stable than cells,
can circulate all over the body, and are able to cross blood–brain barrier (BBB). Moreover, they are
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suitable to be loaded with therapeutic cargos, and they are more resistant to freezing and thawing
procedures than cells, favoring long-term storage [17].
As reviewed before, several studies were conducted to understand EXO function in cardiovascular
physiology and pathology. Through these researches, it emerged that EXOs generated from different
cardiac cell types in different conditions could contain cargo that generates positive or negative effects
on target cells. This gave some ideas on how to exploit EXOs for therapeutic approaches, which can be
divided into two big categories: those that counteract adverse functions of harmful EXOs, and those
that take advantage of and enhance the cardioprotective effects of beneficial EXOs.
4.1. Strategies to Attenuate Adverse Effects of Exosomes
As already mentioned, it was discovered that some factors contained in EXOs generated in
pathological conditions have a detrimental role in cardiovascular diseases.
Studies on EXO biogenesis and trafficking gave suggestions on how to attenuate EXO adverse
effects during diseases, starting from their formation and ending with their release and uptake from
target cells.
To block EXO formation, it was found efficient to inhibit ceramide formation using inhibitors
of neutral sphingomyelinases, such as GW4869, [6], or using amiloride, an anti-hypertensive drug
that blocks Ca2+-dependent MVB formation [52]. Another way seemed to be the inhibition of the
interaction between syndecan proteoglycans and its cytoplasmic adaptor syntetin, which interacts
with programmed cell death-6-interacting protein (PDCD6IP or ALIX), an important protein involved
in EXO biogenesis [53].
Regarding EXO release and uptake from target cells, the various mechanisms through which they
occur are not yet detailed, and the fact that they differ through cell types makes them a difficult target
to approach. Moreover, most studies were performed on tumor cells that represent a very particular
condition, making them difficult to transfer to the cardiovascular field.
All these pathways offer many opportunities to look for right ways to inhibit harmful EXOs;
however, at the same time, interfering with these processes, fundamental also for the regulation and
the maintenance of physiological state, could be dangerous because of off-target effects.
4.2. Strategies to Exploit Exosomes in Cardiovascular Therapy
In the last few years, stem-cell therapies caught attention in many research fields, and were found
to be successful in many cases. However, in the cardiovascular field, they did not appear so promising;
they displayed poor engraftment and survival, as well as the occurrence of arrhythmias and immune
rejection after transplantation [54].
Increasing evidence demonstrated that several cell types, above all stem cells, display their
paracrine effects through EXO release. This shifted the focus from cell therapy to cell-free therapy
approaches, and stem cells represent the most promising EXO source for cardiovascular therapy.
For investigating cardioprotective and cardiac repair effects of EXOs, scientists isolated them
from stem cells of different origin: mesenchymal stem cells (MSCs), induced-pluripotent stem cells
(iPSCs), and CPCs. Arslan et al. were among the first to investigate the role of MSC EXOs on
myocardial ischemia/reperfusion injury, finding that EXO treatment activated pro-survival signaling
by increasing ATP and Nicotinamide adenine dinucleotide (NADH) levels, and decreasing oxidative
stress. Moreover, cardiac function was enhanced and infarct size was reduced [55]. Feng and colleagues
showed that MSCs that underwent ischemic preconditions produced EXOs able to improve cardiac
function after MI, by reducing infarct size and fibrosis [56]. Another work explained that EXOs derived
from MSCs overexpressing GATA-4 resulted enriched in rno-miR-19a, which could be the promoter of
increased CM survival in a hypoxic environment [57].
As already mentioned, EXOs from CPCs also resulted having regenerative potential after
myocardial infarction. Several works demonstrated that they reduce CMs apoptosis, increase tube
formation, and decrease the development of fibrosis. This leads to an improvement in cardiac
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function [36,39,42]. Interestingly, the pretreatment of CPCs with MSC EXOs seems to modify CPC
EXO cargo so as to increase in rno-miR-147 and rno-miR-503-3p levels, and decrease in rno-miR-207,
rno-miR-326-5p, and rno-miR-702-5p levels. These cells, once injected, were shown to promote an
increase in vessel density at the infarct site and to ameliorate cardiac function [58]. When stimulated
with embryonic system-cell (ES) EXOs, CPCs express more CM and EC genes. The injection of
pre-stimulated CPCs resulted in increased cardiac function and reduced infarct size, while the direct
injection of ES MVs/EXOs increased vessel density and improved cardiac function [59].
These studies suggest that changing donor cell conditions is a valid way of modifying EXO
content, potentiating their cardiovascular protection ability. In addition, pretreatment of stem cells
with EXOs derived from other cells can enhance their therapeutic effects.
A curious and unusual study was performed by Middleton and colleagues, who took a cue
from newts, as they can regenerate lost organs and tissues, including the heart, and analyzed the
compatibility of newt EVs with mammalian cells [60]. They extracted EVs form newt myogenic
precursor cells (A1) and, after seeing that, in many ways (size, morphology, content, surface agents,
and GW4869 sensitivity), they were similar to mammalian ones, they treated mammalian CMs with
these vesicles. Gene expression analysis indicated that treated CMs were more resistant to oxidative
stress and, thus, had enhanced cell survival, due to the activation of the Protein kinase B (AKT)
pathway [60]. This evidence makes A1 EXOs and their content interesting candidates for therapeutic
studies in cardiovascular fields.
In addition to the natural effect of stem-cell EXOs, methodologies for loading non-native
cargo continue to be investigated to extend their therapeutic potential (Figure 6). Currently, three
main strategies are available: endogenous encapsulation, and passive or active exogenous cargo
encapsulation. Endogenous loading plans to modify parent cells via transfection or specific treatments,
whereby derived EXOs will reflect the change in parent cells, and part of them will contain the
loaded elements [61,62]. Passive loading methods include the simple incubation of EXOs with drugs
that diffuse into them along the concentration gradient [63]. Instead, the possible methods for the
active encapsulation of selected cargo involve sonication, extrusion, or electroporation [64–66]. These
methods temporally perturb the EXO lipid bilayer, allowing drugs to enter them.
These various approaches have different loading yields, which obviously depend on the properties
of the cargo. The application of these methodologies in cardiovascular diseases is still in its infancy,
but the results obtained treating other pathologies such as cancer generate great expectations.
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5. Exosome Delivery to Target Cells
Despite the many advantages of the possibility of using EXOs as therapy in cardiovascular disease,
a determining factor to make this possible is finding the right way to deliver them so they are effective.
For cardiovascular therapy, the ideal modality to deliver EXOs is obviously intravenous injection;
however, it was demonstrated that this way predominantly led to absorption within the liver [67].
It was then tried to execute intramyocardial (IM) and intracoronary (IC) injections; the comparison
between these two ways highlighted that EXO IM injection was more effective than IC injection [68].
Gallet and colleagues demonstrated that CDC EXO IM injections delivered in infarcted pig heart
showed greater myocardial retention and, as a consequence, a significant decrease in scar size and in
microvascular obstruction compared to IC delivery [68].
Vandergriff et al. highlighted that IM delivery in clinical practice is not the most eligible
method because of its correlated risks [69]. To try solving the problem, they resorted to the
modification of the EXO surface, a heavily researched area which aims to improve targeting of
EXOs to cells of interest. In particular, they tried tagging EXOs with cardiac-homing peptide (CHP),
a peptide that targets infarcted heart, and to inject them into the tail vein of infarcted rats [69]. This
functionalization improved cardiac EXO retention, leading to the induction of CM proliferation,
an increase in angiogenesis, and a reduction in heart fibrosis of infarcted rats [69]. In another
study, Kim and colleagues generated EXOs that expressed cardiac-targeting peptide (CTP) bound
to Lysosomal-associated membrane protein 2b (Lamp2b), an exosomal membrane protein, on the
surface [70]. In vitro and in vivo experiments showed that CTP EXOs were preferentially delivered into
heart cells and tissue, with an increase of 15% [71]. A peptide sequence, CSTSMLKAC, named ischemic
myocardium-targeting peptide (IMTP), which targets ischemic areas of the heart, was discovered by
Kanki et al. [71], and was utilized by Wang and colleagues to engineer the MSC EXO surface such that
its cargo was released into injured CMs [72]. Their hypothesis was confirmed by in vivo experiments
that highlighted a significant increase in targeting ischemic myocardium by IMTP-modified EXOs,
leading to a significant improvement in cardiac health [72].
High retention in the liver is one of the biggest obstacles related to drug delivery, and EXOs
addressed to the heart are not exempt from this problem. However, engineered EXOs seem to
significantly improve the amount that reaches cardiac target cells.
6. Conclusions
The intent of this review was to take stock of the current state of the art regarding EXOs in
cardiovascular diseases. This topic is of the great interest because the study of EXOs is revealing a
lot of new information about paracrine cell communication, which is proving to be fundamental for
the maintenance of physiologic organ homeostasis. Early studies immediately created great prospects
for EXO use as therapy in many diseases, including cardiovascular ones. It soon became clear that
they are advantageous compared to cell therapy, especially in this field, where whole-cell therapy
seemed not promising [54]. Apart from their native properties, which can be exploited in therapy,
they were shown to be suitable for modification so as to target drugs for specific cells and for use as
biomarkers [17,46–51].
Study of the cardiac environment showed an amazing communication network, which exploits
EXOs, between the various cardiac cells. This communication through EXOs was implied in the
maintenance of cardiac homeostasis, but most of all in the adaptive response to stress signals. It follows
that EXOs are involved in many cardiovascular process, having the capability to improve or worsen
cardiac health [10–13]. For these reasons, many studies on EXO functions in cardiovascular disease
continue to be carried out with the hope of exploiting them for developing new therapies for many
cardiovascular pathologies.
In conclusion, this review highlighted that there is still a lot of work to be done before there
are any real opportunities to use EXOs to treat cardiovascular diseases; standardized high-yield and
non-expensive protocols to isolate and characterize EXOs remain to be developed. Furthermore, their
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susceptibility to change makes it difficult to set up scalable and reproducible isolation processes.
There are also no exhaustive studies about EXO kinetics, and many other points need to be deeply
investigated. Instead, their use as biomarkers in the individualization of cardiac acute events might be
a closer goal.
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